While expression of SGLT1 was reduced in SBS patients compared to healthy controls, it was considerably increased in SBS patients treated with teduglutide compared to treatment-naïve SBS patients (Table 3) and its characteristic localization was confirmed by IHC (Figure 4B). This evidence concerns the gene SLC5A1 and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.